JianleWang Ph.D.

Associate

San Diego + 1.858.314.1167

Collegati

Condividi

Dr. Jianle Wang represents pharmaceutical and biotech companies on the procurement and protection of intellectual property. Jianle's practice encompasses global patent portfolio development and management, due diligence investigation, patentability and validity assessments, freedom-to-operate analysis, and patent strategy counseling.

Jianle has experience with a wide range of technologies, including immunotherapies (e.g., antibodies, antibody-drug conjugates, cell-based therapies, CAR-T cell technology), biomarkers and diagnostics, small-molecule pharmaceuticals, cancer treatment, stem cells, and therapeutic polypeptides.

Jianle has worked on representative matters for Merck, AbbVie, and NGM Biopharmaceuticals.

Prior to joining Jones Day, Jianle worked as a scientist for more than 10 years and performed her postdoctoral research at the University of Pennsylvania.

Jianle is actively involved in the Firm's pro bono practice that includes representing individuals seeking asylum in the United States.

Esperienze

  • Epic Sciences builds patent portfolio for clinical applications of single cell diagnosticsJones Day assists Epic Sciences, Inc. with counseling and development of global patent portfolios related to clinical applications of methods for analyzing and categorizing rare circulating cells, such as diagnosing cancers, analyzing heterogeneity of disease, and predicting resistance to therapies.
  • Epic Sciences develops global patent portfolio for diagnostics involving rare circulating cellsJones Day is assisting Epic Sciences, Inc. with counseling and development of global patent portfolios related to methods for analyzing and categorizing rare circulating cells, e.g., circulating tumor cells (CTCs), circulating endothelial cells (CECs).
  • VST Bio establishes global patent portfolios related to anti-syndecan-2 antibodies for the treatment of diseases related to vascular permeabilityJones Day is representing VST Bio Corp. in connection with the establishment of a global patent portfolio related to antibodies that target syndecan-2 and uses thereof in the treatment of diseases related to vascular permeability and leakage, including ischemic stroke and myocardial infarction.
    •

    April 2024 Commentary

    FTC Weighs In on Orange Book Listing of Drug-Device Patents

    Prima di procedere all'invio, si prega di notare:

    il contenuto del presente sito web è a scopo esclusivamente informativo e non può essere considerato un parere legale o altro tipo di consulenza professionale. L'invio o la ricezione della presente email non è atta ad instaurare alcun rapporto cliente/avvocato. Le informazioni inviate tramite questa funzione al nostro Studio non saranno coperte da vincolo di riservatezza o confidenzialità fintanto che non ci sia stato conferito e non sia stato da noi accettato un incarico professionale. Inviando il messaggio confermate di aver preso visione e accettato il contenuto di questa informativa.